Virtual Library

Start Your Search

Yasuhiko Terutya



Author of

  • +

    EP1.09 - Pathology (ID 199)

    • Event: WCLC 2019
    • Type: E-Poster Viewing in the Exhibit Hall
    • Track: Pathology
    • Presentations: 1
    • Now Available
    • Moderators:
    • Coordinates: 9/08/2019, 08:00 - 18:00, Exhibit Hall
    • +

      EP1.09-18 - Comparison of Sample Types with Success Rates of Next-Generation Sequencing (Now Available) (ID 1188)

      08:00 - 18:00  |  Author(s): Yasuhiko Terutya

      • Abstract
      • Slides

      Background

      Precision medicine based on driver oncogenes is now developed for non-small cell lung cancer.Recent approval of next-generation sequencing(NGS)-based companion diagnosics has increased the need for use of high-quality specimens for diagnosis.

      Method

      From December 2013 to May 2018,88 patients who were enrolled in a nation-wide genome screening,LC-SCRUM-Japan,from our institution were examined for the success rates of genetic analysis according to sample types. NGS analysis,NGS Ion SeqTM,Oncomine Comprehensive AssayTM,was performed using DNA and RNA extracted from lung cancer specimens.

      Result

      The success rates of DNA and RNA analyses were 100% (88/88 cases) and 80% (70/88), respectively. Of the 88 samples analyzed, 85 (97%) were tissues and three (3%) were pleural effusions. The success rates of RNA analysis in the 85 tissue samples were 49/64 (77%) in bronchoscopic byopsy, 11/11(100%) in operation, 5/6(83%) in Percutaneous biopsy and 3/4(75%) in others. Of the 64 bronchoscopic samples, the success rates were 74% (20/27) in EBUS-TBNA, 90% (9/10) in EBUS-GS (large diameter), 69% (11/16) in EBUS-GS (small diameter) and 82% (9/11) in direct vision biopsy. In the 88 cases analyzed, a total of 55 actionable gene alterations (20 KRAS mut, 7 MET amp/mut, 6 EGFR mut, 5 RET fus, 5 ALK fus, 4 PIK3CA mut, 2 ERBB2 mut, 2 ROS1 fus, 2 FGFR1 amp, 1 BRAF mut, 1 FGFR3 fus) were detected in 50 cases (57%). Twelve of the 50 (14%) were registered in ongoing clinical trials of targeted drugs.

      Conclusion

      All the samples were available for DNA analysis of the NGS. The success rates of RNA analysis were lower in samples obtained from EBUS-TBNA and EBUS-GS (small diameter), suggesting that the success rates depend on the sample size.

      Only Active Members that have purchased this event or have registered via an access code will be able to view this content. To view this presentation, please login or select "Add to Cart" and proceed to checkout.